Literature DB >> 27162467

Pharmaceutical Approval Update.

Mary Choy.   

Abstract

Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A.

Entities:  

Year:  2016        PMID： 27162467      PMCID： PMC4849335     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  3 in total

1.  Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.

Authors:  Carley M Bogan; Janene M Pierce; Stephanie D Doss; Yuankai K Tao; Sheau-Chiann Chen; Kelli L Boyd; Albert Liao; Terry Hsieh; David H Abramson; Jasmine H Francis; Debra L Friedman; Ann Richmond; Anthony B Daniels
Journal:  Exp Eye Res       Date:  2021-01-11       Impact factor: 3.467

Review 2.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

3.  Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments.

Authors:  Hila Magen; Michal J Simchen; Shira Erman; Abraham Avigdor
Journal:  Ther Adv Hematol       Date:  2022-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.